Literature DB >> 24428256

Differential associations of testosterone, dihydrotestosterone and oestradiol with physical, metabolic and health-related factors in community-dwelling men aged 17-97 years from the Busselton Health Survey.

Bu B Yeap1, Matthew W Knuiman, Mark L Divitini, David J Handelsman, John P Beilby, Jonathan Beilin, Brendan McQuillan, Joseph Hung.   

Abstract

OBJECTIVES: Lower testosterone (T) levels are associated with poorer health outcomes in older men, but associations in younger or middle-aged men are uncertain, and data for dihydrotestosterone (DHT) and oestradiol (E2) are limited. We assessed the associations of circulating T, DHT and E2 with physical and health-related factors in a cohort comprising men aged 17-97 years. PARTICIPANTS AND METHODS: Serum from 2143 community-dwelling men from the 1994/95 Busselton Health Survey was assayed for T, DHT and E2 using liquid chromatography-tandem mass spectrometry. Men receiving hormonal therapy or reporting the use of testosterone, or with prostate cancer or orchidectomy were excluded.
RESULTS: Of the men, 43% had never smoked, 6·1% had diabetes and 16·8% cardiovascular disease (CVD). Mean (±SD) age was 50·3 ± 17·0 years. Total T was moderately correlated with DHT (r = 0·56), E2 (r = 0·35) and sex hormone-binding globulin (r = 0·53). In age-, smoking-, body mass index (BMI)- and sex hormone-binding globulin (SHBG)-adjusted analyses, T was inversely associated with metabolic syndrome score, while DHT and E2 were not associated. In multivariable models, higher total T was associated with lower age, BMI and C-reactive protein, and with higher creatinine and haemoglobin, independently of SHBG. Higher DHT was associated with lower age, BMI and glucose level, and higher creatinine and haemoglobin. E2 was positively associated with age, BMI and haemoglobin.
CONCLUSIONS: In men spanning younger, middle and older ages, circulating androgens are more related to age and metabolic factors than CVD or chronic disease. Further investigation is required to clarify whether androgens and oestrogens have contrasting roles as risk predictors for CVD.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24428256     DOI: 10.1111/cen.12407

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  18 in total

1.  Endotoxin-initiated inflammation reduces testosterone production in men of reproductive age.

Authors:  Kelton Tremellen; Natalie McPhee; Karma Pearce; Sven Benson; Manfred Schedlowski; Harald Engler
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-11-28       Impact factor: 4.310

2.  Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry.

Authors:  Qingqing Wang; Kannan Rangiah; Clementina Mesaros; Nathaniel W Snyder; Anil Vachani; Haifeng Song; Ian A Blair
Journal:  Steroids       Date:  2015-01-29       Impact factor: 2.668

3.  Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study.

Authors:  Yi X Chan; Matthew W Knuiman; Mark L Divitini; David J Handelsman; John P Beilby; Bu B Yeap
Journal:  Horm Cancer       Date:  2018-08-10       Impact factor: 3.869

4.  Aging and estradiol effects on gene expression in the medial preoptic area, bed nucleus of the stria terminalis, and posterodorsal medial amygdala of male rats.

Authors:  Victoria L Nutsch; Margaret R Bell; Ryan G Will; Weiling Yin; Andrew Wolfe; Ross Gillette; Juan M Dominguez; Andrea C Gore
Journal:  Mol Cell Endocrinol       Date:  2016-12-20       Impact factor: 4.102

5.  Higher Dihydrotestosterone Is Associated with the Incidence of Lung Cancer in Older Men.

Authors:  Yi X Chan; Helman Alfonso; S A Paul Chubb; David J Handelsman; P Gerry Fegan; Graeme J Hankey; Jonathan Golledge; Leon Flicker; Bu B Yeap
Journal:  Horm Cancer       Date:  2017-02-23       Impact factor: 3.869

6.  Serum testosterone levels and mortality in men with CKD stages 3-4.

Authors:  Kiranpreet K Khurana; Sankar D Navaneethan; Susana Arrigain; Jesse D Schold; Joseph V Nally; Daniel A Shoskes
Journal:  Am J Kidney Dis       Date:  2014-04-13       Impact factor: 8.860

7.  Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis.

Authors:  Qiu-Ming Yao; Bin Wang; Xiao-Fei An; Jin-An Zhang; Liumei Ding
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

8.  Metabolic endotoxaemia related inflammation is associated with hypogonadism in overweight men.

Authors:  Kelton Tremellen; Natalie McPhee; Karma Pearce
Journal:  Basic Clin Androl       Date:  2017-03-08

Review 9.  The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.

Authors:  Marcello Maggio; Francesca De Vita; Alberto Fisichella; Fulvio Lauretani; Andrea Ticinesi; Graziano Ceresini; Anne Cappola; Luigi Ferrucci; Gian Paolo Ceda
Journal:  Int J Endocrinol       Date:  2015-12-08       Impact factor: 3.257

10.  Gut Endotoxin Leading to a Decline IN Gonadal function (GELDING) - a novel theory for the development of late onset hypogonadism in obese men.

Authors:  Kelton Tremellen
Journal:  Basic Clin Androl       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.